Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification
Open Access
- 8 August 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 28 (1), 81-91
- https://doi.org/10.1002/jbmr.1733
Abstract
Medial vascular calcification (MVC) is common in patients with chronic kidney disease, obesity, and aging. MVC is an actively regulated process that resembles skeletal mineralization, resulting from chondro‐osteogenic transformation of vascular smooth muscle cells (VSMCs). Here, we used mineralizing murine VSMCs to study the expression of PHOSPHO1, a phosphatase that participates in the first step of matrix vesicles‐mediated initiation of mineralization during endochondral ossification. Wild‐type (WT) VSMCs cultured under calcifying conditions exhibited increased Phospho1 gene expression and Phospho1–/– VSMCs failed to mineralize in vitro. Using natural PHOSPHO1 substrates, potent and specific inhibitors of PHOSPHO1 were identified via high‐throughput screening and mechanistic analysis and two of these inhibitors, designated MLS‐0390838 and MLS‐0263839, were selected for further analysis. Their effectiveness in preventing VSMC calcification by targeting PHOSPHO1 function was assessed, alone and in combination with a potent tissue‐nonspecific alkaline phosphatase (TNAP) inhibitor MLS‐0038949. PHOSPHO1 inhibition by MLS‐0263839 in mineralizing WT cells (cultured with added inorganic phosphate) reduced calcification in culture to 41.8% ± 2.0% of control. Combined inhibition of PHOSPHO1 by MLS‐0263839 and TNAP by MLS‐0038949 significantly reduced calcification to 20.9% ± 0.74% of control. Furthermore, the dual inhibition strategy affected the expression of several mineralization‐related enzymes while increasing expression of the smooth muscle cell marker Acta2. We conclude that PHOSPHO1 plays a critical role in VSMC mineralization and that “phosphatase inhibition” may be a useful therapeutic strategy to reduce MVC. © 2013 American Society for Bone and Mineral ResearchKeywords
This publication has 49 references indexed in Scilit:
- Vascular pathology of medial arterial calcifications in NT5E deficiency: Implications for the role of adenosine in pseudoxanthoma elasticumMolecular Genetics and Metabolism, 2011
- PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fracturesBone, 2011
- Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: A unified model of the mechanisms of initiation of skeletal calcificationJournal of Bone and Mineral Research, 2011
- Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chickBone, 2010
- I-TASSER: a unified platform for automated protein structure and function predictionNature Protocols, 2010
- Discovery and Validation of a Series of Aryl Sulfonamides as Selective Inhibitors of Tissue-Nonspecific Alkaline Phosphatase (TNAP)Journal of Medicinal Chemistry, 2009
- Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontinKidney International, 2009
- Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP)Bioorganic & Medicinal Chemistry Letters, 2008
- Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcificationKidney International, 2008
- SWISS-MODEL: an automated protein homology-modeling serverNucleic Acids Research, 2003